| P. aeruginosa from bloodstream infections | MexAB-OprM: 12.3%MexCD-OprJ: 2.2%MexEF-OprN: 4.2%MexXY-OprM: 13.2% | Cefepime-resistant isolates: 25% overexpressed MexAB-OprM and 29% overexpressed MexXY-OprM.MexXY-OprM was the most prevalent efflux pump in tobramycin-resistant isolates (37%), while MexAB-OprM was the most common in meropenem-resistant isolates (33%). | Gabriel et al. (2011) [34] |
| P. aeruginosa from bloodstream infections | MexAB-OprM: 50.8%MexXY-OprM: 27.1% | MexAB-OprM overexpressing isolates showed high resistance to amikacin, gentamicin, and ciprofloxacin (86.7%), while MexXY-OprM overexpressing isolates showed high resistance to cefepime (80%). | Xavier et al. (2010) [35] |
| Ciprofloxacin-resistant P. aeruginosa | MexAB-OprM: 36.5%MexEF-OprN: 11.76%MexXY-OprM: 45.88% | MexEF-OprN may be the main resistance mechanism of P. aeruginosa to fluoroquinolone antibiotics. | Llanes et al. (2011) [36] |
| P. aeruginosa from urinary tract infections | MexAB-OprM: 26.7%MexCD-OprJ: 11.4%MexEF-OprN: 41.9%MexXY-OprM: 38.1% | MexCD-OprJ overexpression was associated with levofloxacin resistance. | Shigemura et al. (2015) [37] |
| Hospital-acquired P. aeruginosa infections | MexAB-OprM: 69%MexCD-OprJ: 28.7%MexEF-OprN: 43.4%MexXY-OprM: 74.6% | Overexpression of MexAB-OprM and MexXY-OprM efflux pumps was highly correlated with bacterial resistance to the treatment antibiotics. | Zahedi bialvaei et al. (2021) [38] |
| Hospital-acquired P. aeruginosa infections | MexAB-OprM: 10.0%MexCD-OprJ: 21.67%MexEF-OprN: 53.33%MexXY-OprM: 5.0% | The overexpression of MexEF-OprN was closely related to the resistance of baceria against cephalosporins, aminosides, and floroquinolones. The resistance of floroquinolone was also found to be related to MexCD-OprJ overexpression | This study |